What is Advanced Cell Diagnostics?
Advanced Cell Diagnostics, Inc. operates at the intersection of biotechnology and precision medicine, specializing in advanced in situ hybridization technologies. The company provides critical tools for RNA detection and quantification, enabling researchers to perform single-cell analysis and multi-omic profiling with unprecedented accuracy. Their product suite, including the industry-standard RNAscope and BaseScope assays, is instrumental in advancing research in oncology, neuroscience, and infectious disease management. Beyond hardware and reagents, the firm offers comprehensive professional assay services and biomarker development, positioning itself as an indispensable partner for biopharma clients seeking to optimize drug development pipelines and clinical diagnostic workflows.
How much funding has Advanced Cell Diagnostics raised?
Advanced Cell Diagnostics has raised a total of $40.8M across 4 funding rounds:
Series A
$5.4M
Series B
$12M
Grant
$1.4M
Series C
$22M
Series A (2009): $5.4M with participation from Morningside Venture Investments
Series B (2012): $12M led by Morningside Ventures and New Leaf Venture
Grant (2014): $1.4M supported by National Cancer Institute
Series C (2015): $22M featuring Kenson Ventures, Summit Partners, Morningside Ventures, and New Leaf Venture Partners
Key Investors in Advanced Cell Diagnostics
Kenson Ventures
A California-based venture investment firm specializing in early-stage and growth-stage biotechnology and life science companies, providing both capital and strategic board-level guidance.
Summit Partners
A prominent equity investment firm founded in 1984 that focuses on supporting entrepreneurial companies with significant growth potential across various sectors.
Morningside Venture Investments
An investment group established by the Chan family, dedicated to private equity and venture capital with a strong emphasis on deep industry knowledge and long-term social responsibility.
What's next for Advanced Cell Diagnostics?
With the recent influx of capital, Advanced Cell Diagnostics is well-positioned to expand its influence in the multi-omic profiling market. The strategic roadmap likely involves deepening its penetration into clinical diagnostic markets, where the demand for high-sensitivity molecular assays is surging. By leveraging its established research-grade technology, the company is poised to transition its diagnostic tools into broader clinical settings, potentially setting new standards for biomarker validation and patient stratification. Future growth will likely focus on scaling operational capacity to meet the increasing global demand for precision diagnostics, while simultaneously fostering new partnerships within the pharmaceutical sector to streamline the integration of their assays into large-scale drug discovery programs.
See full Advanced Cell Diagnostics company page
